Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies

Elisabetta Fratta; Barbara Montico; Aurora Rizzo; Francesca Colizzi; Luca Sigalotti; Riccardo Dolcetti

doi:10.18632/oncotarget.10033

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies

Elisabetta Fratta, Barbara Montico, Aurora Rizzo, Francesca Colizzi, Luca Sigalotti and Riccardo Dolcetti _

PDF | HTML | How to cite

Oncotarget. 2016; 7:57327-57350. https://doi.org/10.18632/oncotarget.10033

Metrics: PDF 2229 views | HTML 4894 views | ?

Abstract

Elisabetta Fratta1, Barbara Montico1, Aurora Rizzo1, Francesca Colizzi1, Luca Sigalotti1 and Riccardo Dolcetti1,2

1 Cancer Bio-Immunotherapy Unit, Centro di Riferimento Oncologico, IRCCS, National Cancer Institute, Aviano, PN, Italy

2 University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia

Correspondence to:

Riccardo Dolcetti, email:

Keywords: hematological malignancies, DNA methylation, histone modifications, azacytidine, 5-aza-2’-deoxycytidine

Received: February 09, 2016 Accepted: May 28, 2016 Published: June 14, 2016

Abstract

In recent years, recurrent somatic mutations in epigenetic regulators have been identified in patients with hematological malignancies. Furthermore, chromosomal translocations in which the fusion protein partners are themselves epigenetic regulators or where epigenetic regulators are recruited/targeted by oncogenic fusion proteins have also been described. Evidence has accumulated showing that “epigenetic drugs” are likely to provide clinical benefits in several hematological malignancies, granting their approval for the treatment of myelodysplastic syndromes and cutaneous T-cell lymphomas. A large number of pre-clinical and clinical trials evaluating epigenetic drugs alone or in combination therapies are ongoing. The aim of this review is to provide a comprehensive summary of known epigenetic alterations and of the current use of epigenetic drugs for the treatment of hematological malignancies.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 10033

Publication Alerts

Reviews:

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies

Abstract